Form 4 for CYTK CYTOKINETICS INC
Accepted 2026-07-23 16:09:01 ET · period of report 2026-07-21 · accession 0001061983-26-000084 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-23 16:09 | 2026-07-21 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $7.80 | +3,500 | 157.4K | +2% | +$27.3K |
| DT | 2026-07-23 16:09 | 2026-07-21 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $80.59 | -3,500 | 153.9K | -2% | -$282.1K |
| DT | 2026-07-23 16:09 | 2026-07-21 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $0.00 | -3,500 | 33.9K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-21 | M | A | 3,500 | $7.80 | 157,402 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-21 | S | D | 3,500 | $80.59 | 153,902 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2026-07-21 | M | D | 3,500 | $0.00 | 33,886 | D | $7.80 · 2018-03-27 to 2028-02-27 | 3,500 Common Stock |